In this case the Committee found at once two types of competition violations. Thus, in the course of investigation on the relations between «Servier Ukraine» LLC and such distributors as Optima-Pharm and BaDM, the AMCU detected anticompetitive concerted actions in the form of taking over the markets of medicinal products of Servier group of companies, which are sold in the territory of Ukraine that led to unjustified increase of prices for medicinal products purchased under public procurement procedures in 2011-2012.
On the other hand, in the contractual relations between «Servier Ukraine» LLC and such distributors as «Alba-Ukraine» LLC, «Lyudmila-Pharm» LLC and «ASTA» LLC the Committee found anticompetitive concerted actions related to the allocation of markets according to the circle of customers in the area of public procurements.
As a result, the following penalties were imposed on the defendants of the case: «Servier Ukraine» LLC – UAH 1 695 691, «Optima-Pharm Ltd» LLC – UAH 179 723, «BaDM» LLC – UAH 902 655, «Alba-Ukraine» LLC – UAH 399 999, «Lyudmila-Pharm» LLC - UAH 25 712, «ASTA» LLC – UAH 423 573.
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.
